Page 2 - Urogen Rtgel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Vincent perroneUrogen rtgelCindy romanoLiz barrettUrogen pharma ltdCorporate communicationsDrug administrationGen pharmaNew drug applicationUtilizing urogenPrivate securities litigation reform actRisk factorsQuarterly reportInvestor relationsUrogen pharma

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesVincent perroneCindy romanoLiz barrettUrogen rtgelCorporate communicationsUrogen pharma ltdDrug administrationGen pharmaNew drug applicationUtilizing urogenPrivate securities litigation reform actRisk factorsQuarterly reportUrogen pharmaBusiness wire

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced a licensing agreement with medac GmbH.

Schleswig holsteinUrogen rtgelLiz barrettDrug administrationUrogen pharma ltdUrogen pharmaNew drug applicationPrivate securities litigation reform actRisk factorsQuarterly report

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

Both ENVISION and ATLAS Phase 3 trials of UGN-102 met primary endpoints in treating low-grade intermediate-risk non‐muscle‐invasive bladder cancer . Reported record JELMYTO® net product. -Today at 08:05 am- MarketScreener

Urogen pharmaUrogen rtgelLiz barrettUrogen pharma ltdDrug administrationChief executive officerNew drug applicationPrepaid forward obligationLong term debtPharmakon advisorsCash equivalentsOperating expenseWebcast informationUpper tract urothelial cancerPrescribing informationPatient information

The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Phase 3 ATLAS Clinical Trial Shows UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 .

Mark schoenbergSandip prasadUrogen rtgelMorristown medical center atlantic health systemUrogen pharma ltdDrug administrationUrogen pharmaChief medical officerGenitourinary surgical oncologyMorristown medicalAtlantic health systemChief investigatorNew drug applicationPrivate securities litigation reform actRisk factorsQuarterly report